Author: admin

The Pulmonary Arterial Hypertension Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Pulmonary Arterial Hypertension Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Pulmonary Arterial Hypertension Market.

Some of the key takeaways from the Pulmonary Arterial Hypertension Pipeline Report: 

• Companies across the globe are diligently working toward developing novel Pulmonary Arterial Hypertension treatment therapies with a considerable amount of success over the years. 
• Pulmonary Arterial Hypertension companies working in the treatment market are Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others, are developing therapies for the Pulmonary Arterial Hypertension treatment 

• Emerging Pulmonary Arterial Hypertension therapies in the different phases of clinical trials are- MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others are expected to have a significant impact on the Pulmonary Arterial Hypertension market in the coming years. 
• In March 2024, Merck (NYSE: MRK), also known as MSD outside the United States and Canada, has announced today that the U.S. Food and Drug Administration (FDA) has given approval for sotatercept-csrk (U.S. Brand Name: WINREVAIR™, for injection, 45mg, 60mg) for the management of pulmonary arterial hypertension (PAH) in adults. This medication is indicated to enhance exercise capacity, ameliorate World Health Organization (WHO) functional class (FC), and mitigate the risk of clinical worsening events. WINREVAIR had previously received Breakthrough Therapy Designation from the FDA. It represents the first FDA-approved therapy targeting activin signaling inhibition for PAH, offering a novel therapeutic approach by modulating the balance between pro- and anti-proliferative signaling to regulate vascular cell proliferation associated with PAH.
• In January 2024, Pulnovo Medical Limited, a globally renowned innovator in medical devices for treating Pulmonary Hypertension (PH) and Heart Failure (HF), has recently achieved Humanitarian Use Device (HUD) designation from the US FDA and approval from China’s National Medical Products Administration (NMPA) for the PADN Catheter and Generator. The PADN technology marks a significant breakthrough in the realm of global interventional pulmonary arterial hypertension (PAH), addressing challenges in PAH interventional therapy 
• In July 2022, Cereno Scientific reported the initiation of the Phase II clinical trial for drug candidate CS1 in pulmonary arterial hypertension (PAH), with the enrollment of the first patient.
• Gossamer Bio, Inc. has disclosed significant preclinical data affirming the potential of seralutinib in the treatment of pulmonary arterial hypertension (PAH).

Pulmonary Arterial Hypertension Overview

Pulmonary Arterial Hypertension (PAH) is a type of high blood pressure that specifically affects the arteries in the lungs and the right side of the heart. In PAH, the small arteries in the lungs, called pulmonary arteries, become narrowed, blocked, or damaged. This increases the resistance to blood flow through the lungs, leading to elevated blood pressure in the pulmonary arteries.

Get a Free Sample PDF Report to know more about Pulmonary Arterial Hypertension Pipeline Therapeutic Assessment- 

https://www.delveinsight.com/report-store/pulmonary-arterial-hypertension-pipeline-insight

Emerging Pulmonary Arterial Hypertension Drugs Under Different Phases of Clinical Development Include:

• MGX292: Centessa Pharmaceuticals
• RBM-011: Ribomic
• GMA301: Gmax Biopharm LLC.
• LTP001: Novartis Pharmaceuticals
• CS1: Cereno Scientific AB
• Treprostinil Palmitil: Insmed Incorporated
• AV-101: Aerovate Therapeutics
• L606: Pharmosa Biopharm Inc

Pulmonary Arterial Hypertension Route of Administration

Pulmonary Arterial Hypertension pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical
• Molecule Type

Pulmonary Arterial Hypertension Molecule Type

Pulmonary Arterial Hypertension Products have been categorized under various Molecule types, such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

• Pulmonary Arterial Hypertension Assessment by Product Type
• Pulmonary Arterial Hypertension By Stage and Product Type
• Pulmonary Arterial Hypertension Assessment by Route of Administration
• Pulmonary Arterial Hypertension By Stage and Route of Administration
• Pulmonary Arterial Hypertension Assessment by Molecule Type
• Pulmonary Arterial Hypertension by Stage and Molecule Type

DelveInsight’s Pulmonary Arterial Hypertension Report covers around 55+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Pulmonary Arterial Hypertension product details are provided in the report. Download the Pulmonary Arterial Hypertension pipeline report to learn more about the emerging Pulmonary Arterial Hypertension therapies

Some of the key companies in the Pulmonary Arterial Hypertension Therapeutics Market include:

Key companies developing therapies for Pulmonary Arterial Hypertension are – VasThera Co Ltd, Altavant Sciences Inc, Alterras Therapeutics GmbH, United Therapeutics Corp, Chiesi Farmaceutici SpA, Gmax Biopharm LLC, Antlia Bioscience Inc, and others.

Pulmonary Arterial Hypertension Pipeline Analysis:

The Pulmonary Arterial Hypertension pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Pulmonary Arterial Hypertension with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pulmonary Arterial Hypertension Treatment.
• Pulmonary Arterial Hypertension key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Pulmonary Arterial Hypertension Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Pulmonary Arterial Hypertension market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Pulmonary Arterial Hypertension drugs and therapies

Pulmonary Arterial Hypertension Pipeline Market Drivers

• Rising prevalence of Pulmonary Arterial Hypertension worldwide, robust Drug pipeline and the new product combinations are some of the important factors that are fueling the Pulmonary Arterial Hypertension Market.

Pulmonary Arterial Hypertension Pipeline Market Barriers

• However, high cost associated with the treatment of Pulmonary Arterial Hypertension, lack of awareness among people in developing countries and other factors are creating obstacles in the Pulmonary Arterial Hypertension Market growth.

Scope of Pulmonary Arterial Hypertension Pipeline Drug Insight    

• Coverage: Global
• Key Pulmonary Arterial Hypertension Companies: Centessa Pharmaceuticals, Ribomic, Gmax Biopharm LLC., Novartis Pharmaceuticals, Cereno Scientific AB, Insmed Incorporated, Aerovate Therapeutics, Pharmosa Biopharm Inc, and others
• Key Pulmonary Arterial Hypertension Therapies: MGX292, RBM-011, GMA301, LTP001, CS1, Treprostinil Palmitil, AV-101, L606, and others
• Pulmonary Arterial Hypertension Therapeutic Assessment: Pulmonary Arterial Hypertension current marketed and Pulmonary Arterial Hypertension emerging therapies
• Pulmonary Arterial Hypertension Market Dynamics: Pulmonary Arterial Hypertension market drivers and Pulmonary Arterial Hypertension market barriers 

Request for Sample PDF Report for Pulmonary Arterial Hypertension Pipeline Assessment and clinical trials

Table of Contents

1. Pulmonary Arterial Hypertension Report Introduction

2. Pulmonary Arterial Hypertension Executive Summary

3. Pulmonary Arterial Hypertension Overview

4. Pulmonary Arterial Hypertension- Analytical Perspective In-depth Commercial Assessment

5. Pulmonary Arterial Hypertension Pipeline Therapeutics

6. Pulmonary Arterial Hypertension Late Stage Products (Phase II/III)

7. Pulmonary Arterial Hypertension Mid Stage Products (Phase II)

8. Pulmonary Arterial Hypertension Early Stage Products (Phase I)

9. Pulmonary Arterial Hypertension Preclinical Stage Products

10. Pulmonary Arterial Hypertension Therapeutics Assessment

11. Pulmonary Arterial Hypertension Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Pulmonary Arterial Hypertension Key Companies

14. Pulmonary Arterial Hypertension Key Products

15. Pulmonary Arterial Hypertension Unmet Needs

16 . Pulmonary Arterial Hypertension Market Drivers and Barriers

17. Pulmonary Arterial Hypertension Future Perspectives and Conclusion

18. Pulmonary Arterial Hypertension Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Pulmonary Arterial Hypertension Pipeline and Clinical Trials Assessment, 2024 Updates: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Ribomic, Gmax Biopharm LLC., Novartis

The Non-Alcoholic Steatohepatitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Non-Alcoholic Steatohepatitis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Non-Alcoholic Steatohepatitis Market.

Some of the key takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report:

• Companies across the globe are diligently working toward developing novel Non-Alcoholic Steatohepatitis treatment therapies with a considerable amount of success over the years. 
• Non-Alcoholic Steatohepatitis companies working in the treatment market are Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others, are developing therapies for the Non-Alcoholic Steatohepatitis treatment 

• Emerging Non-Alcoholic Steatohepatitis therapies in the different phases of clinical trials are- GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others are expected to have a significant impact on the Non-Alcoholic Steatohepatitis market in the coming years.   
• In March 2024, Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical firm specializing in innovative therapies for nonalcoholic steatohepatitis (NASH), has disclosed today that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Rezdiffra (resmetirom). This approval is for its use alongside diet and exercise in the treatment of adults diagnosed with noncirrhotic NASH with moderate to advanced liver fibrosis (corresponding to stages F2 to F3 fibrosis). The continuation of approval for this indication may be subject to confirmation and delineation of clinical benefits in ongoing confirmatory studies.
• In April 2023, Resmetirom has been given the FDA’s Breakthrough Therapy designation for treating NASH patients with liver fibrosis, according to a statement from Madrigal Pharmaceuticals. The enrollment process for the Phase 3 MAESTRO-NASH biopsy trial’s outcomes component has been completed, the company added in its announcement.
• In March 2023, On HORIZON, a randomised Phase 2b non-alcoholic steatohepatitis (NASH) clinical trial (NCT05583344), PathAI announced its collaboration with GSK (LSE/NYSE: GSK). Participants in the trial with NASH and advanced fibrosis will have their improvements in liver histology with GSK4532990 measured in comparison to placebo. With the use of its AI-based Measurement of NASH Histology (AIM-NASH) tool, PathAI will be responsible for creating, digitising, and analysing liver biopsy slides for examination by a central pathologist1. AIM-NASH measurements will be used in this study as exploratory endpoints.
• In March 2023, ALG-055009, a thyroid receptor-beta (THR-ß) agonist candidate from Aligos Therapeutics, was presented with Phase 1 results at the 15th Paris Hepatology Conference, which will really take place March 27 through March 29, 2023.
• In March 2023, Positive results from DESTINY-1 (Deuterium-stabilized R-pioglitazone [PXL065] Efficacy and Safety Trial In NASH), a 36-week dose-ranging Phase 2 trial, were published in the Journal of Hepatology, according to POXEL SA. PXL065 is a brand-new, proprietary pioglitazone R-stereoisomer with lower PPAR activity but still the same non-genomic pioglitazone effects.
• In January 2023, The FDA has accepted Intercept Pharmaceuticals’ New Drug Application (NDA) for obeticholic acid (OCA), which was submitted in order to obtain accelerated clearance for the treatment of patients with pre-cirrhotic liver fibrosis brought on by nonalcoholic steatohepatitis (NASH).
• In January 2023, Resmetirom, a liver-directed selective thyroid hormone receptor agonist, was tested in the major Phase III MAESTRO-NASH biopsyclinical trial by Madrigal Pharmaceuticals, Inc. At the NASH-TAG Conference, fresh MAESTRO-NASH results are being presented.
• In August 2022, An international, multi-center, double-blind, randomised, and placebo-controlled trial was started by Madrigal Pharmaceuticals with patients who had well-compensated NASH cirrhosis. For the duration of the study and until the required number of Composite Clinical Outcome events are attained, participants will be randomised 3:1 in a blinded manner to receive 80 mg of resmetirom or a matching placebo administered orally once daily in the morning.
• In July 2022, To assess the safety, efficacy, pharmacokinetics, and pharmacodynamics of orally administered TERN-501 as monotherapy and in combination with TERN-101 in noncirrhotic adults with presumed non-alcoholic steatohepatitis (NASH), TERN Therapeutics started a Phase IIa multicenter, randomised, double-blind, placebo-controlled clinical study.

Non-Alcoholic Steatohepatitis Overview

Non-alcoholic steatohepatitis (NASH) is liver damage and inflammation brought on by an accumulation of fat. It belongs to a class of diseases known as nonalcoholic fatty liver disease. Nonalcoholic steatohepatitis (NASH), which includes fat, inflammation, and liver cell destruction, can be distinguished from isolated fatty liver, which simply manifests as fat buildup.

Get a Free Sample PDF Report to know more about Non-Alcoholic Steatohepatitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/non-alcoholic-steatohepatitis-nash-pipeline-insight

Emerging Non-Alcoholic Steatohepatitis Drugs Under Different Phases of Clinical Development Include:

• GMA-107: Gmax Biopharm
• LBS-009: Lin Biosciences
• VK-1430: Viking Therapeutics
• SRT-015: Seal Rock Therapeutics
• AZD 2693: AstraZeneca
• BI 456906: Boehringer Ingelheim
• ORMD-0801: Oramed Pharmaceuticals
• EYP001: ENYO Pharma
• TERN-501: Terns Pharmaceuticals
• Semaglutide: NovoNordisk
• Resmetirom: Madrigal Pharmaceuticals
• Lanifibranor: Inventiva Pharma

Non-Alcoholic Steatohepatitis Route of Administration

Non-Alcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Non-Alcoholic Steatohepatitis Molecule Type

Non-Alcoholic Steatohepatitis Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

• Non-Alcoholic Steatohepatitis Assessment by Product Type
• Non-Alcoholic Steatohepatitis By Stage and Product Type
• Non-Alcoholic Steatohepatitis Assessment by Route of Administration
• Non-Alcoholic Steatohepatitis By Stage and Route of Administration
• Non-Alcoholic Steatohepatitis Assessment by Molecule Type
• Non-Alcoholic Steatohepatitis by Stage and Molecule Type

DelveInsight’s Non-Alcoholic Steatohepatitis Report covers around 110+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Non-Alcoholic Steatohepatitis product details are provided in the report. Download the Non-Alcoholic Steatohepatitis pipeline report to learn more about the emerging Non-Alcoholic Steatohepatitis therapies

Some of the key companies in the Non-Alcoholic Steatohepatitis Therapeutics Market include:

Key companies developing therapies for Non-Alcoholic Steatohepatitis are – Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Inventiva, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, 89bio, Inc., Enanta Pharmaceuticals, Inc, Eccogene, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Arrowhead Pharma, LG Chem, Redx Pharma, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Aligos Therapeutics, Altimmune, Inc., Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, Hepagene Therapeutics, HighTide Biopharma, and others.

Non-Alcoholic Steatohepatitis Pipeline Analysis:

The Non-Alcoholic Steatohepatitis pipeline report provides insights into 

•  The report provides detailed insights about companies that are developing therapies for the treatment of Non-Alcoholic Steatohepatitis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Non-Alcoholic Steatohepatitis Treatment.
• Non-Alcoholic Steatohepatitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Non-Alcoholic Steatohepatitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Non-Alcoholic Steatohepatitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Non-Alcoholic Steatohepatitis drugs and therapies

Non-Alcoholic Steatohepatitis Pipeline Market Drivers

• Rise in Non-Alcoholic Steatohepatitis prevalence, emerging Non-Alcoholic Steatohepatitis treatment therapies of NASH, growing demand for NASH therapeutics are some of the important factors that are fueling the Non-Alcoholic Steatohepatitis Market.

Non-Alcoholic Steatohepatitis Pipeline Market Barriers

• However, lack of analogs, use of combination therapies, reimbursement issues and other factors are creating obstacles in the Non-Alcoholic Steatohepatitis Market growth.

Scope of Non-Alcoholic Steatohepatitis Pipeline Drug Insight    

• Coverage: Global
• Key Non-Alcoholic Steatohepatitis Companies: Gmax Biopharm, Lin Biosciences, Viking Therapeutics, Seal Rock Therapeutics, AstraZeneca, Boehringer Ingelheim, Oramed Pharmaceuticals, ENYO Pharma, Terns Pharmaceuticals, NovoNordisk, Madrigal Pharmaceuticals, Inventiva Pharma, and others
• Key Non-Alcoholic Steatohepatitis Therapies: GMA-107, LBS-009, VK-1430, SRT-015, AZD 2693, BI 456906, ORMD-0801, EYP001, TERN-501, Semaglutide, Resmetirom, Lanifibranor, and others
• Non-Alcoholic Steatohepatitis Therapeutic Assessment: Non-Alcoholic Steatohepatitis current marketed and Non-Alcoholic Steatohepatitis emerging therapies
• Non-Alcoholic Steatohepatitis Market Dynamics: Non-Alcoholic Steatohepatitis market drivers and Non-Alcoholic Steatohepatitis market barriers 

Request for Sample PDF Report for Non-Alcoholic Steatohepatitis Pipeline Assessment and clinical trials

Table of Contents

1. Non-Alcoholic Steatohepatitis Report Introduction

2. Non-Alcoholic Steatohepatitis Executive Summary

3. Non-Alcoholic Steatohepatitis Overview

4. Non-Alcoholic Steatohepatitis- Analytical Perspective In-depth Commercial Assessment

5. Non-Alcoholic Steatohepatitis Pipeline Therapeutics

6. Non-Alcoholic Steatohepatitis Late Stage Products (Phase II/III)

7. Non-Alcoholic Steatohepatitis Mid Stage Products (Phase II)

8. Non-Alcoholic Steatohepatitis Early Stage Products (Phase I)

9. Non-Alcoholic Steatohepatitis Preclinical Stage Products

10. Non-Alcoholic Steatohepatitis Therapeutics Assessment

11. Non-Alcoholic Steatohepatitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Non-Alcoholic Steatohepatitis Key Companies

14. Non-Alcoholic Steatohepatitis Key Products

15. Non-Alcoholic Steatohepatitis Unmet Needs

16 . Non-Alcoholic Steatohepatitis Market Drivers and Barriers

17. Non-Alcoholic Steatohepatitis Future Perspectives and Conclusion

18. Non-Alcoholic Steatohepatitis Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Viking Therapeutics, AstraZeneca, Oramed Pharma

The Esophageal Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Esophageal Cancer Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Esophageal Cancer Market.

Some of the key takeaways from the Esophageal Cancer Pipeline Report:

• Companies across the globe are diligently working toward developing novel Esophageal Cancer treatment therapies with a considerable amount of success over the years. 
• Esophageal Cancer companies working in the treatment market are CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others, are developing therapies for the Esophageal Cancer treatment 

• Emerging Esophageal Cancer therapies in the different phases of clinical trials are- CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others are expected to have a significant impact on the Esophageal Cancer market in the coming years.   
• In March 2024, BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global leader in oncology, has announced today that the U.S. Food and Drug Administration (FDA) has granted approval for TEVIMBRA® (tislelizumab-jsgr) as a standalone treatment for adult patients suffering from unresectable or metastatic esophageal squamous cell carcinoma (ESCC) who have previously undergone systemic chemotherapy that did not involve a PD-(L)1 inhibitor. TEVIMBRA is expected to be accessible in the U.S. market during the latter half of 2024.
• In September 2022, Integral Molecular has granted CARTEXELL a license for a series of monoclonal antibodies (MAbs) to facilitate the development of CAR-T cell therapies utilizing Integral Molecular’s Claudin 18.2 (CLDN18.2) MAbs. The agreement entails an exclusive global license for CARTEXELL to utilize the set of CLND18.2 MAbs, known for their high specificity, high affinity, and complete humanization, for the creation of CAR-T cell therapies targeting solid tumors such as gastric, lung, pancreatic, and esophageal cancers. CARTEXELL assumes sole responsibility for all research, development, and commercial endeavors as per the terms of the agreement
• In August 2022, BeiGene disclosed that the China National Medical Products Administration’s (NMPA) Center for Drug Evaluation (CDE) has approved a supplemental biologics license application (sBLA) for tislelizumab. The application pertains to the use of tislelizumab in combination with chemotherapy for the initial treatment of patients diagnosed with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma (ESCC).
• In May 2022, Shanghai Junshi Biosciences Co., Ltd, revealed that the China National Medical Products Administration (NMPA) sanctioned the supplemental new drug application (sNDA) for toripalimab in conjunction with paclitaxel and cisplatin. This approval is for the initial treatment of patients facing unresectable locally advanced/recurrent or distant metastatic esophageal squamous cell carcinoma (ESCC). The NMPA accepted the sNDA in July 2021, marking toripalimab’s fifth approved indication in China. This decision is expected to significantly benefit Chinese patients coping with advanced ESCC.
• In May 2022, Bristol Myers Squibb reported the U.S. Food and Drug Administration’s (FDA) approval for both Opdivo (nivolumab) in combination with fluoropyrimidine- and platinum-containing chemotherapy and Opdivo with Yervoy (ipilimumab) as the initial treatment for adult patients dealing with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC), irrespective of their PD-L1 status. These approvals are grounded on the Phase III CheckMate -648 trial, which investigated Opdivo combined with chemotherapy (n=321) and Opdivo plus Yervoy (n=325) in comparison to chemotherapy alone (n=324). This trial represents the most extensive Phase III study in first-line ESCC immunotherapy.

Esophageal Cancer Overview

The development of cancer cells in the esophagus, a long, tube-like tissue that connects the throat and the stomach, results in esophageal cancer. As a component of the upper digestive system, the esophagus transports food that has been swallowed to the stomach. Squamous cell carcinoma and adenocarcinoma are the two primary kinds.

Get a Free Sample PDF Report to know more about Esophageal Cancer Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/esophageal-cancer-pipeline-insight

Emerging Esophageal Cancer Drugs Under Different Phases of Clinical Development Include:

• CDR404: CDR-Life Inc.
• M1231: Merck KGaA
• Sotigalimab: Apexigen
• Amivantamab: Genmab
• Telomelysin: Oncolys BioPharma Inc
• Tiragolumab: Genentech
• S-588410: Onco Therapy Science, Inc. /Shionogi & Co., Ltd.
• CS1001: CStone Pharmaceuticals
• Durvalumab: Celgene/MedImmune
• Tucatinib: Seagen
• APX 005M: Apexigen
• Erdafitinib: Janssen Research & Development, LLC
• Margetuximab: MacroGenics
• AN-0025: Adlai Nortye

Esophageal Cancer Route of Administration

Esophageal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Esophageal Cancer Molecule Type

Esophageal Cancer Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Esophageal Cancer Pipeline Therapeutics Assessment

• Esophageal Cancer Assessment by Product Type
• Esophageal Cancer By Stage and Product Type
• Esophageal Cancer Assessment by Route of Administration
• Esophageal Cancer By Stage and Route of Administration
• Esophageal Cancer Assessment by Molecule Type
• Esophageal Cancer by Stage and Molecule Type

DelveInsight’s Esophageal Cancer Report covers around 80+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Esophageal Cancer product details are provided in the report. Download the Esophageal Cancer pipeline report to learn more about the emerging Esophageal Cancer therapies

Some of the key companies in the Esophageal Cancer Therapeutics Market include:

Key companies developing therapies for Esophageal Cancer are – Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Exelixis, Bayer, BeiGene, Lyell Immunopharma, Sichuan Baili Pharmaceutical, AP Biosciences.,Leap Therapeutics, Inc., Adlai Nortye Biopharma Co., Ltd., Athenex, Inc., Pfizer, Genentech, Hangzhou Neoantigen Therapeutics, Janssen Pharmaceutical, Curis, Inc.,Merck KGaA, Apexigen, Inc,Shenzhen Hornetcorn Bio-technology Company, LTD, MacroGenics, Bristol-Myers Squibb, Integral Molecular, CARTEXELL, EMD Serono, and others.

Esophageal Cancer Pipeline Analysis:

The Esophageal Cancer pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Cancer with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Cancer Treatment.
• Esophageal Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Esophageal Cancer drugs and therapies

Esophageal Cancer Pipeline Market Drivers

• Increase in the number of cases of Esophageal Cancer, increasing research and development and launches of novel products by key players are some of the important factors that are fueling the Esophageal Cancer Market.

Esophageal Cancer Pipeline Market Barriers

• However, high cost of therapy for the treatment of esophageal cancer, side effects associated with the current treatment options and other factors are creating obstacles in the Esophageal Cancer Market growth.

Scope of Esophageal Cancer Pipeline Drug Insight    

• Coverage: Global
• Key Esophageal Cancer Companies: CDR-Life Inc., Merck KGaA, Apexigen, Genmab, Oncolys BioPharma Inc, Genentech, Onco Therapy Science, Inc., Shionogi & Co., Ltd., CStone Pharmaceuticals, Celgene, MedImmune, Seagen, Apexigen,Janssen Research & Development, MacroGenics, Adlai Nortye, and others
• Key Esophageal Cancer Therapies: CDR404, M1231, Sotigalimab, Amivantamab, Telomelysin, Tiragolumab, S-588410, CS1001, Durvalumab, Tucatinib, APX 005M, Erdafitinib, Margetuximab, AN-0025, and others
• Esophageal Cancer Therapeutic Assessment: Esophageal Cancer current marketed and Esophageal Cancer emerging therapies
• Esophageal Cancer Market Dynamics: Esophageal Cancer market drivers and Esophageal Cancer market barriers 

Request for Sample PDF Report for Esophageal Cancer Pipeline Assessment and clinical trials

Table of Contents

1. Esophageal Cancer Report Introduction

2. Esophageal Cancer Executive Summary

3. Esophageal Cancer Overview

4. Esophageal Cancer- Analytical Perspective In-depth Commercial Assessment

5. Esophageal Cancer Pipeline Therapeutics

6. Esophageal Cancer Late Stage Products (Phase II/III)

7. Esophageal Cancer Mid Stage Products (Phase II)

8. Esophageal Cancer Early Stage Products (Phase I)

9. Esophageal Cancer Preclinical Stage Products

10. Esophageal Cancer Therapeutics Assessment

11. Esophageal Cancer Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Esophageal Cancer Key Companies

14. Esophageal Cancer Key Products

15. Esophageal Cancer Unmet Needs

16 . Esophageal Cancer Market Drivers and Barriers

17. Esophageal Cancer Future Perspectives and Conclusion

18. Esophageal Cancer Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Cancer Pipeline Assessment, 2024 | In-depth Insights into the Emerging Drugs, Latest FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Outlook | Oncolys BioPharma Inc, Genentech

“Chemotherapy induced diarrhea Market”

DelveInsight’s “Chemotherapy induced diarrhea Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Chemotherapy induced diarrhea, historical and forecasted epidemiology as well as the Chemotherapy induced diarrhea market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Chemotherapy induced diarrhea market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Chemotherapy induced diarrhea market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Chemotherapy induced diarrhea treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Chemotherapy induced diarrhea market.

Request for a Free Sample Report @ Chemotherapy induced diarrhea Market forecast

Some facts of the Chemotherapy induced diarrhea market report are:

• According to DelveInsight, the Chemotherapy induced diarrhea market is expected to grow at a decent CAGR by 2032.
• The total Chemotherapy induced diarrhea market size in the 7MM accounted for ~USD 80 million in 2022, which is expected to rise with a significant CAGR during the study period (2019–2032).
• Key Chemotherapy-induced Diarrhea Pipeline Therapies: FW-420, Mytesi, DP 1038, OQL051 and others.
• Leading Chemotherapy induced diarrhea companies working in the treatment market are AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, OnQuality Pharmaceuticals, Helsinn Healthcare and others.
• On March 2024, Helsinn Healthcare announced results of a randomized, stratified, double-blind, double-dummy, parallel group, placebo-controlled, dose finding, multicentre, multinational, phase II study in patient with colorectal cancer receiving 5- Fluorouracil (5-FU)-based chemotherapy (FOLFOX or FOLFIRI). Patients will receive, starting from the day of chemotherapy administration, a single daily dose subcutaneously (s.c.) of elsiglutide 10, 20 or 40 mg or placebo for 4 consecutive days. Each patient will be in the study for 3 consecutive chemotherapy cycles. The treatment period for each patient will be 4 consecutive days at each of the first 2 chemotherapy cycles.

Chemotherapy induced diarrhea Overview

Chemotherapy-induced diarrhea (CID) is a common and distressing side effect of cancer treatment that occurs due to the toxic effects of chemotherapy drugs on the gastrointestinal tract. It typically presents as frequent, watery stools and can range from mild to severe, potentially leading to dehydration, electrolyte imbalances, and treatment interruptions. Chemotherapy-induced diarrhea is caused by damage to the lining of the intestines, which disrupts normal bowel function and increases fluid secretion. Certain chemotherapy drugs, such as 5-fluorouracil, irinotecan, and targeted therapies, are more commonly associated with Chemotherapy-induced diarrhea. Management strategies for Chemotherapy-induced diarrhea may include anti-diarrheal medications, dietary modifications, fluid replacement therapy, and dose adjustments or discontinuation of chemotherapy drugs. Prevention and early intervention are key in managing Chemotherapy-induced diarrhea to improve patient comfort, maintain treatment adherence, and prevent complications that may impact overall cancer therapy outcomes.

Learn more about Chemotherapy induced diarrhea, treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market

Chemotherapy induced diarrhea Market

The Chemotherapy induced diarrhea market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Chemotherapy induced diarrhea market trends by analyzing the impact of current Chemotherapy induced diarrhea therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Chemotherapy induced diarrhea market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chemotherapy induced diarrhea market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Chemotherapy induced diarrhea market in 7MM is expected to witness a major change in the study period 2019-2032.

Chemotherapy induced diarrhea Epidemiology

The Chemotherapy induced diarrhea epidemiology section provides insights into the historical and current Chemotherapy induced diarrhea patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Chemotherapy induced diarrhea market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Chemotherapy induced diarrhea Epidemiology @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market

Chemotherapy induced diarrhea Drugs Uptake

This section focuses on the uptake rate of the potential Chemotherapy induced diarrhea drugs recently launched in the Chemotherapy induced diarrhea market or expected to be launched in 2019-2032. The analysis covers the Chemotherapy induced diarrhea market uptake by drugs, patient uptake by therapies, and sales of each drug.

Chemotherapy induced diarrhea Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Chemotherapy induced diarrhea market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Chemotherapy induced diarrhea Pipeline Development Activities

The Chemotherapy induced diarrhea report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Chemotherapy induced diarrhea key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Chemotherapy induced diarrhea pipeline development activities @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market

Chemotherapy induced diarrhea Therapeutics Assessment

Major key companies are working proactively in the Chemotherapy induced diarrhea Therapeutics market to develop novel therapies which will drive the Chemotherapy induced diarrhea treatment markets in the upcoming years are AzuRx BioPharma, Napo Pharmaceuticals, Dauntless Pharmaceuticals, Helsinn Healthcare OnQuality Pharmaceuticals and others.

Learn more about the emerging therapies & key companies @ https://www.delveinsight.com/sample-request/chemotherapy-induced-diarrhea-market

Chemotherapy induced diarrhea Report Key Insights

1. Chemotherapy induced diarrhea Patient Population

2. Chemotherapy induced diarrhea Market Size and Trends

3. Key Cross Competition in the Chemotherapy induced diarrhea Market

4. Chemotherapy induced diarrhea Market Dynamics (Key Drivers and Barriers)

5. Chemotherapy induced diarrhea Market Opportunities

6. Chemotherapy induced diarrhea Therapeutic Approaches

7. Chemotherapy induced diarrhea Pipeline Analysis

8. Chemotherapy induced diarrhea Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Chemotherapy induced diarrhea Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Chemotherapy induced diarrhea Competitive Intelligence Analysis

4. Chemotherapy induced diarrhea Market Overview at a Glance

5. Chemotherapy induced diarrhea Disease Background and Overview

6. Chemotherapy induced diarrhea Patient Journey

7. Chemotherapy induced diarrhea Epidemiology and Patient Population

8. Chemotherapy induced diarrhea Treatment Algorithm, Current Treatment, and Medical Practices

9. Chemotherapy induced diarrhea Unmet Needs

10. Key Endpoints of Chemotherapy induced diarrhea Treatment

11. Chemotherapy induced diarrhea Marketed Products

12. Chemotherapy induced diarrhea Emerging Therapies

13. Chemotherapy induced diarrhea Seven Major Market Analysis

14. Attribute Analysis

15. Chemotherapy induced diarrhea Market Outlook (7 major markets)

16. Chemotherapy induced diarrhea Access and Reimbursement Overview

17. KOL Views on the Chemotherapy induced diarrhea Market

18. Chemotherapy induced diarrhea Market Drivers

19. Chemotherapy induced diarrhea Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Chemotherapy induced diarrhea Market Analysis 2032: Epidemiology, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals, Clinical Trials and Companies by DelveInsight

“Rheumatoid Arthritis Market”

(Albany, USA) DelveInsight’s “Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Rheumatoid Arthritis, historical and forecasted epidemiology as well as the Rheumatoid Arthritis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Rheumatoid Arthritis market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Rheumatoid Arthritis market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Rheumatoid Arthritis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Rheumatoid Arthritis market.

Request for a Free Sample Report @ Rheumatoid Arthritis Market Forecast

Some facts of the Rheumatoid Arthritis Market Report are:

• According to DelveInsight, Rheumatoid Arthritis market size is expected to grow at a decent CAGR by 2032.
• As per DelveInsight analysis, the rheumatoid arthritis market size in the 7MM was approximately USD 27 billion in 2021.
• According to the assessment done by DelveInsight, the estimated total rheumatoid arthritis prevalent population in the 7MM was approximately 4.7 million in 2021.
• Leading Rheumatoid Arthritis companies working in the market are Taisho Pharmaceuticals, R-Pharm, GlaxoSmithKline, Aclaris Therapeutics, Pfizer, Abivax, Bristol Myers Squibb, Oscotec/Genosco, Mesoblast, Pfizer Akros Pharma/Japan Tobacco, Abbvie, Horizon Therapeutics, Eli Lilly and Company, Taiho Pharmaceutical, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, SynAct Pharma, Cyxone, and others.
• Key Rheumatoid Arthritis Therapies expected to launch in the market are Ozoralizumab (TS-152), Artlegia (Olokizumab), Otilimab (GSK3196165/ MOR103), Zunsemetinib (ATI-450), Ritlecitinib (PF-06651600), ABX464, Branebrutinib, Cevidoplenib (SKI-O-703), MPC-300-IV, PF-06650833, JTE -051, ABBV-154, TAS5315, MBS2320, AMT-101, AP1189, Rabeximod (Rob 803), and others.
• On Jan 2024, Rise Therapeutics announced A Single and Repeat Dosing Study of the Safety, Drug Exposure and Clinical Activity of R-2487 in Patients With Rheumatoid Arthritis.
• On April 2024, IGM Biosciences announced a Phase 1b, randomized, placebo-controlled, multicentre study to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of imvotamab in adult participants with active RA who are refractory or intolerant to 2 previous biologic disease-modifying anti-rheumatic drugs (bDMARD) or targeted synthetic disease-modifying anti-rheumatic drugs (tsDMARD) therapies. Approximately 24 participants will be sequentially assigned to different dose escalation cohorts.
• On March 2024, Sanofi announced a Phase 2 Randomized, Double-blind, Placebo-controlled, Dose-ranging, Efficacy and Safety Study of SAR441566 Plus Methotrexate in Adults With Moderate to Severe Rheumatoid Arthritis

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is a chronic autoimmune disease that primarily affects the joints, causing inflammation, pain, swelling, and stiffness. It can also affect other organs and systems in the body. Rheumatoid arthritis occurs when the immune system mistakenly attacks the synovium, the lining of the membranes that surround the joints, leading to inflammation and damage to cartilage and bone.

The exact cause of Rheumatoid arthritis is unknown, but genetic, environmental, and hormonal factors are believed to play a role. It typically affects women more often than men and can develop at any age, although it most commonly starts between the ages of 30 and 60.

Treatment for Rheumatoid arthritis aims to control symptoms, prevent joint damage, and improve quality of life. This often involves a combination of medications (such as disease-modifying anti rheumatic drugs and biologic agents), lifestyle changes, physical therapy, and sometimes surgery. Early diagnosis and intervention are key to managing Rheumatoid arthritis effectively and reducing long-term complications.

Learn more about Rheumatoid Arthritis treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Rheumatoid Arthritis Market 

The Rheumatoid Arthritis market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Rheumatoid Arthritis market trends by analyzing the impact of current Rheumatoid Arthritis therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Rheumatoid Arthritis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Rheumatoid Arthritis market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Over the last few years, there has been a dramatic improvement in rheumatoid arthritis outcomes as a direct result of paradigm shifts in rheumatoid arthritis treatment. At the moment, the main rheumatoid arthritis treatment options are Medicine (for long-term relief of symptoms and slowing the progression of the condition), Supportive treatments (including physiotherapy and occupational therapy, to help keep the patient mobile and manage any problems related to daily activities), and Surgery (to correct any joint problems that develop over a period of time). Nonsteroidal anti-inflammatory drugs (NSAIDs) are typically used only for symptomatic treatment until a rheumatoid arthritis diagnosis is established because they reduce pain and stiffness in patients but have no effect on disease progression.

According to DelveInsight, the Rheumatoid Arthritis market in 7MM is expected to witness a major change in the study period 2019-2032.

Rheumatoid Arthritis Epidemiology 

The Rheumatoid Arthritis epidemiology section provides insights into the historical and current Rheumatoid Arthritis patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Rheumatoid Arthritis market report also provides the diagnosed patient pool, trends, and assumptions. 

Explore more about Rheumatoid Arthritis Epidemiology @ Rheumatoid Arthritis Market Dynamics

Rheumatoid Arthritis Drugs Uptake

This section focuses on the uptake rate of the potential Rheumatoid Arthritis drugs recently launched in the Rheumatoid Arthritis market or expected to be launched in 2019-2032. The analysis covers the Rheumatoid Arthritis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Rheumatoid Arthritis Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Rheumatoid Arthritis market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Rheumatoid Arthritis Pipeline Development Activities

The Rheumatoid Arthritis report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Rheumatoid Arthritis key players involved in developing targeted therapeutics.

• Artlegia (Olokizumab): R-Pharm
• TS-152 (Ozoralizumab): Taisho Pharmaceuticals
• Otilimab (GSK3196165/MOR103): GlaxoSmithKline
• ATI-450 (Zunsemetinib/CDD-450): Aclaris Therapeutics
• Branebrutinib: Bristol Myers Squibb
• LY3462817: Eli Lilly and Company
• TAS5315: Taiho Pharmaceutical
• Rabeximod (Rob 803): Cyxone
• GS-5718: Gilead Sciences
• KPL-404: Kiniksa Pharmaceuticals
• MBS2320: Istesso
• AMT-101: Applied Molecular Transport
• Dazodalibep (HZN-4920): Horizon Therapeutics
• Cevidoplenib (SKI-O-703): Genosco/Oscotec
• HB-AdMSCs: Hope Biosciences
• ABX464: Abivax
• MPC-300-IV: Mesoblast
• PF-06650833: Pfizer
• JTE 051: Akros Pharma/Japan Tobacco
• Dekavil (F8IL10): Pfizer/Philogen
• ABBV-154: AbbVie
• PF-06651600 (Ritlecitinib): Pfizer
• AP1189: SynAct Pharma

Request for a sample report to understand more about the Rheumatoid Arthritis pipeline development activities @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Rheumatoid Arthritis Therapeutics Assessment

Major key companies are working proactively in the Rheumatoid Arthritis Therapeutics market to develop novel therapies which will drive the Rheumatoid Arthritis treatment markets in the upcoming years are R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly and Company, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco/Oscotec, Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, Pfizer, SynAct Pharma, Incyte Corporation, Immunex, UCB, Astellas Pharma, Roche, Galapagos, Gilead Sciences, Swedish Orphan Biovitrium (SOBI), and others.

Learn more about the emerging Rheumatoid Arthritis therapies & key companies @ https://www.delveinsight.com/sample-request/rheumatoid-arthritis-ra-market

Rheumatoid Arthritis Report Key Insights

1. Rheumatoid Arthritis Patient Population

2. Rheumatoid Arthritis Market Size and Trends

3. Key Cross Competition in the Rheumatoid Arthritis Market

4. Rheumatoid Arthritis Market Dynamics (Key Drivers and Barriers)

5. Rheumatoid Arthritis Market Opportunities

6. Rheumatoid Arthritis Therapeutic Approaches

7. Rheumatoid Arthritis Pipeline Analysis

8. Rheumatoid Arthritis Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Rheumatoid Arthritis Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Rheumatoid Arthritis Competitive Intelligence Analysis

4. Rheumatoid Arthritis Market Overview at a Glance

5. Rheumatoid Arthritis Disease Background and Overview

6. Rheumatoid Arthritis Patient Journey

7. Rheumatoid Arthritis Epidemiology and Patient Population

8. Rheumatoid Arthritis Treatment Algorithm, Current Treatment, and Medical Practices

9. Rheumatoid Arthritis Unmet Needs

10. Key Endpoints of Rheumatoid Arthritis Treatment

11. Rheumatoid Arthritis Marketed Products

12. Rheumatoid Arthritis Emerging Therapies

13. Rheumatoid Arthritis Seven Major Market Analysis

14. Attribute Analysis

15. Rheumatoid Arthritis Market Outlook (7 major markets)

16. Rheumatoid Arthritis Access and Reimbursement Overview

17. KOL Views on the Rheumatoid Arthritis Market

18. Rheumatoid Arthritis Market Drivers

19. Rheumatoid Arthritis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Rheumatoid Arthritis Market Analysis 2032: Epidemiology, Market Size and Share, FDA Approval, Clinical Trials and Companies by DelveInsight